Fabomotizole

Fabomotizole

Systematic (IUPAC) name
5-Ethoxy-2-[2-(morpholino)-ethylthio]benzimidazole
Clinical data
Trade names	Afobazole
Legal status	US: Not approved
Routes of administration	Oral
Pharmacokinetic data
Bioavailability	43.64%, pronounced first-pass effect
Metabolism	extensive hepatic
Onset of action	0.85±0.13 hours
Biological half-life	0.82±0,54 hours
Identifiers
CAS Number	173352-39-1 N
ATC code	N05BX04 (WHO)
PubChem	CID: 9862937
ChemSpider	8038633 Y
UNII	HDO6HX6NZU Y
Synonyms	Fabomotizole
Chemical data
Formula	C15H21N3O2S
Molecular mass	307.410 g/mol
SMILES C3COCCN3CCSc(nc1c2)nc1ccc2OCC
InChI InChI=1S/C15H21N3O2S/c1-2-20-12-3-4-13-14(11-12)17-15(16-13)21-10-7-18-5-8-19-9-6-18/h3-4,11H,2,5-10H2,1H3,(H,16,17) Y Key:WWNUCVSRRUDYPP-UHFFFAOYSA-N Y
NY (what is this?)  (verify)

Fabomotizole (INN) (brand name Afobazole) is an anxiolytic drug launched in Russia in the early 2000s. It produces anxiolytic and neuroprotective effects without any sedative or muscle relaxant actions. Its mechanism of action remains poorly defined however, with GABAergic, NGF- and BDNF-release-promoting, MT1 receptor agonism, MT3 receptor antagonism, and sigma agonism suggested as potential mechanisms. Fabomotizole was shown to inhibit MAO-A reversibly and there might be also some involvement with serotonin receptors. Clinical trials have shown fabomotizole to be well tolerated and reasonably effective for the treatment of anxiety.

Experiments of mice have shown antimutagenic and antiteratogenic properties.

Fabomotizole has found little clinical use outside Russia and has not been evaluated by the FDA.